Agios Pharmaceuticals Inc Revenue Growth Rates (AGIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Agios Pharmaceuticals Inc   (NASDAQ: AGIO)
 

AGIO's Revenue Growth by Quarter and Year

Agios Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AGIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 44.75
1st Quarter March 20.75
FY 65.50





AGIO Revenue second quarter 2026 Y/Y Growth Comment
Agios Pharmaceuticals Inc achieved in the second quarter 2026, above Company average Revenue surge of 259.11% year on year, to $ 44.75 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue growth. While Agios Pharmaceuticals Inc ' s Revenue doubling of 259.11% ranks overall at the positon no. 1465 in the second quarter 2026.


AGIO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 86.11 % 51.13 % 64.73 %
3rd Quarter September - 43.75 % 21.08 % 110.23 %
2nd Quarter June 259.11 % 44.55 % 28.46 % 20.25 %
1st Quarter March 137.69 % 6.59 % 45.99 % 575.9 %
FY   - 48.05 % 36.09 % -

Financial Statements
Agios Pharmaceuticals Inc 's second quarter 2026 Revenue $ 44.75 millions AGIO's Income Statement
Agios Pharmaceuticals Inc 's second quarter 2025 Revenue $ 12.46 millions Quarterly AGIO's Income Statement


AGIO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 55.05 % 19.75 % -4.05 %
3rd Quarter September - 3.37 % 3.94 % 10.28 %
2nd Quarter June 115.64 % 42.73 % 5.25 % 19.61 %
1st Quarter March 3.91 % -18.64 % 15.35 % 30.16 %
FY (Year on Year)   - 48.05 % 36.09 % -


Back to AGIO Growth rate Comparisons >> Back to AGIO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #247
Overall #1465

Revenue Y/Y Growth Statistics
High Average Low
229.16 % 50.65 % -47.94 %
(Mar 31 2015)   (Jun 30 2016)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #247
Overall #1465
Revenue Y/Y Growth Statistics
High Average Low
229.16 % 50.65 % -47.94 %
(Mar 31 2015)   (Jun 30 2016)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Agios Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
570.91 % 38.28 % -100 %
(Jun 30 2022)  


AGIO's II. Quarter Q/Q Revenue Comment
Agios Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 115.64%, to $ 44.75 millions, from $20.75 millions in the first quarter.
AGIO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Agios Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 122.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #42
Overall #122
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #42
Overall #122
Revenue Q/Q Growth Statistics
High Average Low
570.91 % 38.28 % -100 %
(Jun 30 2022)  


AGIO's II. Quarter Q/Q Revenue Comment
Agios Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 115.64%, to $ 44.75 millions, from $20.75 millions in the first quarter.
AGIO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Agios Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 122.


Agios Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 98.34 $ 66.05 $ 54.03 $ 44.79 $ 40.88
Y / Y Revenue Growth (TTM) 140.58 % 78.34 % 48.03 % 36.26 % 30.57 %
Year on Year Revenue Growth Overall Ranking # 556 # 507 # 82 # 291 # 48
Seqeuential Revenue Change (TTM) 48.89 % 22.25 % 20.62 % 9.58 % 10.37 %
Seq. Revenue Growth (TTM) Overall Ranking # 1465 # 2025 # 359 # 1526 # 549


Cumulative Revenue growth Comment
Agios Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 140.58% year on year, to $ 98 millions if the fiscal year would have ended in Jun 30 2026.
Agios Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 50.65% and higher than 78.34% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 48.89 % from $66.05 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at50.65%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 48.89 % increase from $66.05 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 125 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 507 to 556.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 82
Healthcare Sector # 126
Overall # 556

Revenue TTM Y/Y Growth Statistics
High Average Low
229.16 %
 50.65 %
-47.94 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 82
Sector # 247
S&P 500 # 1465
Cumulative Revenue growth Comment
Agios Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 140.58% year on year, to $ 98 millions if the fiscal year would have ended in Jun 30 2026.
Agios Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 50.65% and higher than 78.34% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 48.89 % from $66.05 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at50.65%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 48.89 % increase from $66.05 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 125 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 507 to 556.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 82
Healthcare Sector # 126
Overall # 556

Revenue TTM Y/Y Growth Statistics
High Average Low
229.16 %
50.65 %
-47.94 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 82
Sector # 247
S&P 500 # 1465




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AGIO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions


About Agios Pharmaceuticals Inc Revenue Growth Rates (AGIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Agios Pharmaceuticals Inc (CIK 1439222).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001439222-26-000118
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Agios Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.